Catalyst Event
Novartis AG (NVS) · Other
From KEDI Global Longevity Bio Index (KGLB)
6/1/2026, 12:00:00 AM
New data for Cosentyx, ianalumab, and Scemblix to be presented at the EULAR and ASCO 2026 congresses on 2026-06-01, highlighting positive results in immunology and oncology scheduled. Medium importance is estimated as clinical data for key drugs typically drives a 5% market reaction scheduled.
Korean Translation
2026년 6월 1일 EULAR 및 ASCO 2026 학회에서 코센틱스, 이아날루맙, 셈블릭스에 대한 새로운 데이터를 발표하고 면역학 및 종양학 분야의 긍정적인 결과를 강조할 예정임. 주요 약물의 임상 데이터 발표는 통상적으로 5% 수준의 주가 변동을 야기하므로 'Medium'으로 예정됨.
Related Recent Events
Exelixis Inc (EXEL) · Other
U.S. FDA PDUFA target action date for zanzalintinib (December 3, 2026) is a potential first approval for a major new franchise; >10% price impact is estimated, scheduled.
12/3/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Other
The U.S. FDA set a PDUFA target action date for iberdomide on 2026-08-17; importance is Low as the setting of a PDUFA date is a procedural event with minor price impact.
8/17/2026, 12:00:00 AM
Moderna Inc (MRNA) · Other
FDA Prescription Drug User Fee Act (PDUFA) target action date for its seasonal flu vaccine (mRNA-1010) on August 5, 2026; Medium importance as PDUFA dates are major catalysts for biotech stocks, scheduled.
8/5/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
Next quarterly earnings for Q2 2026 are expected to be announced on August 4, 2026; medium impact estimated based on historical volatility during earnings releases, expected.
8/4/2026, 12:00:00 AM
Sanofi (SNY) · Earnings Release
Sanofi's Q2 2026 earnings results release on July 30, 2026, is expected to have a Medium impact as earnings typically drive 5-10% price volatility scheduled.
7/30/2026, 12:00:00 AM
AbbVie Inc (ABBV) · Earnings Release
Q2 2026 earnings release for 2026-07-30. Low importance as it is a routine announcement scheduled.
7/30/2026, 12:00:00 AM